SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-001975
Filing Date
2023-02-24
Accepted
2023-02-24 09:26:18
Documents
15
Period of Report
2023-02-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20230224x8k.htm   iXBRL 8-K 39194
2 EX-99.1 plx-20230224xex99d1.htm EX-99.1 35549
3 GRAPHIC plx-20230224xex99d1001.jpg GRAPHIC 5450
4 GRAPHIC plx-20230224xex99d1002.jpg GRAPHIC 11361
  Complete submission text file 0001558370-23-001975.txt   228284

Data Files

Seq Description Document Type Size
5 EX-101.SCH plx-20230224.xsd EX-101.SCH 3257
6 EX-101.LAB plx-20230224_lab.xml EX-101.LAB 16018
7 EX-101.PRE plx-20230224_pre.xml EX-101.PRE 10763
9 EXTRACTED XBRL INSTANCE DOCUMENT plx-20230224x8k_htm.xml XML 4864
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 23662764
SIC: 2836 Biological Products, (No Diagnostic Substances)